Home / Data / Women's Health Trial Tracker Women's Health Trial Tracker Women's Health Trial Tracker organizes records from ClinicalTrials.gov API v2 into a static table for transparent comparison. It preserves official source links and dates, marks missing enrichment, and adds deterministic grouping, change, recency, trend, or significance fields only where the documented inputs support them, without recommendations or unsupported claims.
Records 5,000
Last changed 10/10/2026
Update schedule 55 1 * * * UTC
Coverage 05/26/2000–10/09/2026 Record Record Date Vuga Group Change Status Recency Days Research Attention Score A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) 02/11/2019 INTERVENTIONAL not-comparable 2,798.75 0 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI) 02/15/2019 INTERVENTIONAL not-comparable 2,794.75 0 Modulating Early Life Microbiome Through Dietary Intervention in Crohn's Disease 02/22/2019 INTERVENTIONAL not-comparable 2,787.75 0 FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation (II) 02/26/2019 INTERVENTIONAL not-comparable 2,783.75 0 A Trial to Evaluate Safety, Tolerability, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine 02/26/2019 INTERVENTIONAL not-comparable 2,783.75 0 Laparotomy Versus Percutaneous Endoscopic Correction of Myelomeningocele 02/27/2019 INTERVENTIONAL not-comparable 2,782.75 0 Oral Dydrogesterone as Luteal Phase Support in Natural Cycle FET 03/01/2019 INTERVENTIONAL not-comparable 2,780.75 0 SALpingectomy for STERilization (SALSTER) 03/04/2019 INTERVENTIONAL not-comparable 2,777.75 0 Exploring the Efficacy and Feasibility of the LymphaTech Scanner for Breast Cancer-Related Lymphedema Screening 03/05/2019 INTERVENTIONAL not-comparable 2,776.75 0 Determining Prognostic Immune Markers in Patients With Ovarian Cancer 03/05/2019 OBSERVATIONAL not-comparable 2,776.75 0 Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease 03/07/2019 INTERVENTIONAL not-comparable 2,774.75 0 Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients 03/12/2019 INTERVENTIONAL not-comparable 2,769.75 0 Best Start - Weight Management During Pregnancy 03/14/2019 INTERVENTIONAL not-comparable 2,767.75 0 Transdermal Estrogen in Women With Anorexia Nervosa 03/14/2019 INTERVENTIONAL not-comparable 2,767.75 0 Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: 03/14/2019 INTERVENTIONAL not-comparable 2,767.75 0 Vaginal Native Tissues Repair for Pelvic Organ Prolapse 03/15/2019 INTERVENTIONAL not-comparable 2,766.75 0 Evaluation of the Accuracy of Percutaneous Biopsy by Vacuum-assisted Biopsy (VAB) to Assess Pathological Complete Response in Patients With Clinical and Radiological Complete Response After Neoadjuvant Chemotherapy (NeoVAB) 03/15/2019 INTERVENTIONAL not-comparable 2,766.75 0 Clinical Pre-screening Protocol for Ovarian Cancer 03/18/2019 OBSERVATIONAL not-comparable 2,763.75 0 Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast 03/18/2019 INTERVENTIONAL not-comparable 2,763.75 0 Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer 03/18/2019 INTERVENTIONAL not-comparable 2,763.75 0 Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer 03/19/2019 INTERVENTIONAL not-comparable 2,762.75 0 A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma 03/19/2019 INTERVENTIONAL not-comparable 2,762.75 0 Sub-type Specific Genomic Mutations in sBOTs 03/21/2019 OBSERVATIONAL not-comparable 2,760.75 0 Attitudes and Decision-making After Pregnancy Testing Study 03/25/2019 OBSERVATIONAL not-comparable 2,756.75 0 Real World Study of Biosimilar Trastuzumab in Her2 Positive Breast Cancer 03/27/2019 OBSERVATIONAL not-comparable 2,754.75 0 Robotic-Assisted da Vinci System Prophylactic Nipple-Sparing Mastectomy 03/27/2019 INTERVENTIONAL not-comparable 2,754.75 0 Safety of IBD Drugs During Pregnancy and Breastfeeding: Mothers and Babies' Outcomes (DUMBO Registry) 03/28/2019 OBSERVATIONAL not-comparable 2,753.75 0 Photoacoustic Imaging of the Breast in Patients With Breast Cancer and Healthy Subjects 04/01/2019 INTERVENTIONAL not-comparable 2,749.75 0 PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate 04/03/2019 INTERVENTIONAL not-comparable 2,747.75 0 Preimplantation Genetic Testing for Aneuploidies in Patients With Recurrent Implantation Failure 04/03/2019 INTERVENTIONAL not-comparable 2,747.75 0 Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer 04/03/2019 INTERVENTIONAL not-comparable 2,747.75 0 Effect of Prednisolone Treatment on Uterine Natural Killer Cells 04/04/2019 INTERVENTIONAL not-comparable 2,746.75 0 Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer 04/09/2019 INTERVENTIONAL not-comparable 2,741.75 0 Oxytocin Receptor Expression in Pregnancy 04/09/2019 OBSERVATIONAL not-comparable 2,741.75 0 Fit-for-Fertility Multicenter Randomized Controlled Trial 04/09/2019 INTERVENTIONAL not-comparable 2,741.75 0 Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma 04/10/2019 INTERVENTIONAL not-comparable 2,740.75 0 DAISy-PCOS Phenome Study - Dissecting Androgen Excess and Metabolic Dysfunction in Polycystic Ovary Syndrome 04/11/2019 OBSERVATIONAL not-comparable 2,739.75 0 Study of Treatment for HPV16+ ASC-US or LSIL 04/12/2019 INTERVENTIONAL not-comparable 2,738.75 0 Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer 04/16/2019 INTERVENTIONAL not-comparable 2,734.75 0 The Pregnancy & Early Life Study 04/16/2019 OBSERVATIONAL not-comparable 2,734.75 0 Autologous PRP Intra Ovarian Infusion to Restore Ovarian Function in Menopausal Women 04/16/2019 INTERVENTIONAL not-comparable 2,734.75 0 Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer 04/16/2019 INTERVENTIONAL not-comparable 2,734.75 0 Single Pre-Operative Radiation Therapy - With Delayed Surgery for Low Risk Breast Cancer 04/17/2019 INTERVENTIONAL not-comparable 2,733.75 0 Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes 04/22/2019 OBSERVATIONAL not-comparable 2,728.75 0 Transcriptome Profiling and Endometrial Receptivity 04/24/2019 OBSERVATIONAL not-comparable 2,726.75 0 Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection 04/25/2019 INTERVENTIONAL not-comparable 2,725.75 0 Abbreviated Breast MRI (AB-MRI) With Golden-angle Radial Compressed-sensing and Parallel Imaging (GRASP) 04/25/2019 OBSERVATIONAL not-comparable 2,725.75 0 Consequences of Unwanted Pregnancy in Nepal 04/29/2019 OBSERVATIONAL not-comparable 2,721.75 0 Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial Cancer 04/30/2019 INTERVENTIONAL not-comparable 2,720.75 0 Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer 05/03/2019 INTERVENTIONAL not-comparable 2,717.75 0
Source U.S. National Library of Medicine, ClinicalTrials.gov API v2 · official record · retrieved 10/10/2026 · upstream last modified 10/10/2026
Licence United States government work; public domain unless the source record says otherwise. Source: U.S. National Library of Medicine
Required notice Study records are informational and do not provide diagnosis, treatment advice, or an assessment of individual risk. What we add We compute Vuga Group, Change Status, Recency Days, Research Attention Score using the documented compute method. · methodology